Article Sidebar

Submitted
Apr 21, 2021
Published
Apr 21, 2021
Download
PDF
Statistic
Read Counter : 51 Download : 27

Main Article Content

Abstract

Much of the scientific justification for using methadone to treat women with heroin use disorders relies on one heavily cited early review of five studies. The review concluded there were no long-term developmental effects directly associated with prenatal methadone exposure because scores for exposed infants on the Psychomotor Development Index (PDI) of the Bayley Scales of Infant Development fell “well within the normal range of development.”  However, three of the studies reviewed reported significant differences between exposed and control infants on the PDI.  The other two did not report scores on the PDI.  The PDI is a subscale of the Bayley Scales of Infant Development, which was released with a much more extensive normative sample in 1993. Extrapolating PDI scores from the earlier version to the better 1993 version reveals that methadone-exposed infants were not well within the normal range of development. Given the increasingly higher doses of methadone used to treat pregnant opioid-dependent women, we are concerned about the potential for greater adverse effects in the present era.  Beginning with the seminal review, this paper examines subsequent studies for longitudinal outcomes for prenatally exposed infants. We hypothesize that revised BSID-II PDI scores will reveal motor effects for infants born to women with heroin use disorders treated with methadone.

Keywords

Methadone Longitudinal Outcomes Prenatal exposure Bayley Scales

Article Details

How to Cite
Sherry Dingman, Maria E. MelilliOtte, William VanOrnum, & Rachel Trainque. (2021). Longitudinal effects of in utero methadone exposure on development using revised norms on the Bayley Scales of Infant Development (BSID). International Journal of Research in Pharmacology & Pharmacotherapeutics, 6(2), 242-246. https://doi.org/10.61096/ijrpp.v6.iss2.2017.242-246
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Finnegan, L. Treatment issues for opioid dependent women during the perinatal period. J of Psychoactive Drugs. 23, 1991, 191-201.
  2. [2]. Kaltenbach K, Silverman N, Wapner, R. Methadone maintenance during pregnancy. In: State Methadone Treatment Guideline. U.S. Department of Health and Human Services. Rockville, MD. 1992, 85-93.
  3. [3]. Joseph H, Stancliff, S, Langrod, J. Methadone maintenance treatment MMT: a review of historical and clinical issues. Mt Sinai J Med. 67, 2000, 347-364.
  4. [4]. Kaltenbach,K, Finnegan LP. Developmental outcome of children born to methadone-maintained women: A review of longitudinal studies. Neurobehav toxicology and teratology. 6, 1984, 231-275.
  5. [5]. Strauss ME, Starr RH, Ostrea EM, Chavez CJ, Stryker JC. Behavioral concomitants of prenatal addiction to narcotics. J. Pediatrics. 89, 1976, 842-846.
  6. [6]. Wilson GS, Desmond MM, Wait RB. Follow up of methadone treated women and their infants: Health, developmental, and social implications. J. Pediatr. 98, 1981, 716-722.
  7. [7]. Rosen TS, Johnson HL. Children of methadone maintained mother: follow-up to 18 months of age. J. Pediatrics.101, 1982, 192-196.
  8. [8]. Zhu JJ. personal communication. Dr. Zhu was the statistician at Pearson, the company that now sells the Bayley.
  9. [9]. Hans SL. Developmental Consequences of prenatal exposure to methadone. Ann N Y Acad Sci. 562, 1989, 195-207.
  10. [10]. Hans SL, Marcus J. Motoric and attentional behavior in infants of methadone-maintained women. NIDA Res Monogr. 43, 1983 287-293.
  11. [11]. The American College of Obstetricians and Gynecologists. Opioid abuse, dependence, and addiction in pregnancy. Committee on Health Care for underserved women and the American Society of Addiction Medicine. 2012 reaffirmed 2016.
  12. [12]. Hunt RW, Tzioumi D, Collins E, Jeffery HE. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev. 84, 2008, 29-35.
  13. [13]. Teraski LS, Gomez J, Schwarz JM. An examination of sex differences in effects of early-life opiate and alcohol exposure. Phil.Trans. Soc. B. 371, 2016, 20150123.
  14. [14]. Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer, G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction. 103, 2008, 1429-1440.
  15. [15]. Cantell MH, Smyth MM, Ahonen TP. Two distinct pathways for developmental coordination disorder: persistence and resolution. Hum Mov Sci. 22, 2003, 413-431.
  16. [16]. Rosen TS, Johnson HL. Long-term effects of prenatal methadone maintenance. NIDA Res. Monogr. 59, 1985, 73-83.
  17. [17]. Farid WO, Dunlop, SA, Tait RJ, Hulse GK. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. CurrNeuropharmacol. 6, 2008, 125-150.
  18. [18]. Sanchez ES, Bigbee JW, Fobbs W, Robinson, SE, Sato-Bigbee, C. Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain. Glia. 56, 2008, 1017-1027.
  19. [19]. Kaltenbach K, Finnegan LP. Perinatal and developmental outcome of infants exposed to methadone in-utero. Neurotoxicol. Teratol. 9, 1987, 311-313.
  20. [20]. Strauss ME, Lessen-Firestone JK, Chavez CJ, Stryker, JC. Children of methadone- treated women at five years of age. Pharmacol. Biochem. Behav. 11, 1979, 3-6.